Indications and Contraindications
The WELL program is specifically designed for the treatment of addiction to Alcohol and Opiates (Heroin, Morphine, Codeine, Methadone, OxyContin, Vicodin, Darvocet, Percocet, etc.) through the use of ground-breaking Ketamine-enhanced psychotherapy, coupled with innovative techniques of alternative medicine.
In addition to being highly effective in the treatment of patients with Alcoholism and Opioid dependence, Ketamine-enhanced psychotherapy is also proven to successfully treat many other emotional problems and mental disorders. Preliminary data show that Ketamine-enhanced psychotherapy is useful in the treatment of other types of addiction (stimulants and sedatives), anxiety, phobias, post-traumatic stress disorder, psychosomatic illnesses, depression, hypochondriasis and neurotic personality disorders, as well as death anxiety in individuals dying from cancer or other incurable diseases. It also assists conscious personal transformation and works well with existential problems, transpersonal issues and mid-life metamorphosis.
Eleusis, however, is dedicated to the treatment of clients with a primary diagnosis of Alcohol and/or Opiate addictions only. We do not specialize in the treatment of other addictions, mental illnesses or psychosomatic disorders. Nevertheless, clients with dual diagnosis who have concurrent addictions in addition to Alcoholism and Opioid dependence may still be accepted into the program as long as the primary diagnosis is Alcohol and/or Opiate addictions. The same rule applies to clients who have coexisting emotional problems, psychosomatic disorders and/or mental illnesses in addition to a primary diagnosis of Alcoholism and Opioid dependence. The Eleusis selection committee makes each acceptance decision on an individual basis.
Eleusis does not maintain an emergency department, nor does it provide medical treatment in all disciplines of medicine. Therefore, the WELL program does not accept those with clinically unstable disorders, including cardiovascular, hepatic, renal, gastrointestinal, pulmonary, metabolic, endocrine, neurological or other systemic diseases.
Those with clinically unstable psychiatric disorders characterized by psychotic symptoms, such as dementia, schizophrenia or bipolar disorder, are also not appropriate candidates. The WELL program does not accept people with the presence of suicidal ideations.
The experience of Ketamine is much more profound when there is no previous history of the use of “psychedelic” drugs. Therefore, a history of repeated use of hallucinogenic compounds diminishes the effects of the Ketamine experience and may significantly decrease the results of the treatment.
Certain other medications, such as benzodiazepines, opiates and barbiturates, may interact adversely with or obscure the action of Ketamine. Therefore, those who take any of these medications would not benefit from our program.
The effects of Ketamine on an unborn child are not known, and it is not known whether undergoing Ketamine-enhanced psychotherapy now can have effects on unborn children in the future. Pregnant women, nursing mothers and women who can have children who are not using effective birth control are not candidates for the WELL program.
Ketamine-enhanced psychotherapy has not been studied on children and the elderly; therefore, the program is open only to individuals between the ages of 21 and 64.